Thursday - July 16, 2026
Johnson & Johnson statement on investigational programs in large B-cell lymphoma
April 30, 2026
NEW BRUNSWICK, New Jersey, April 30 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

Johnson & Johnson statement on investigational programs in large B-cell lymphoma

*

RARITAN, N.J., APRIL 30, 2026 - The investigational CD20 mono CAR-T cell therapy and CD19-CD20 bi-CAR-T programs will be discontinued. This is a strategic business decision based on the Company's portfolio priorities and . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products